Your browser doesn't support javascript.
loading
Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score.
Pai, Rish K; Jairath, Vipul; Hogan, Malcolm; Zou, Guangyong; Adeyi, Oyedele A; Anstee, Quentin M; Aqel, Bashar A; Behling, Cynthia; Carey, Elizabeth J; Clouston, Andrew D; Corey, Kathleen; Feagan, Brian G; Kleiner, David E; Ma, Christopher; McFarlane, Stefanie C; Noureddin, Mazen; Ratziu, Vlad; Valasek, Mark A; Younossi, Zobair M; Harrison, Stephen A; Loomba, Rohit.
Afiliação
  • Pai RK; Department of Laboratory Medicine & Pathology, Mayo Clinic Arizona, Scottsdale, Arizona, USA.
  • Jairath V; Division of Gastroenterology, Department of Medicine, University of Western Ontario, London, Ontario, Canada.
  • Hogan M; Alimentiv Inc., London, Ontario, Canada.
  • Zou G; Department of Epidemiology and Biostatistics, University of Western Ontario, London, Ontario, Canada.
  • Adeyi OA; Alimentiv Inc., London, Ontario, Canada.
  • Anstee QM; Alimentiv Inc., London, Ontario, Canada.
  • Aqel BA; Department of Epidemiology and Biostatistics, University of Western Ontario, London, Ontario, Canada.
  • Behling C; Robarts Research Institute, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada.
  • Carey EJ; Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
  • Clouston AD; Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, UK.
  • Corey K; NIHR Newcastle Biomedical Research Center, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK.
  • Feagan BG; Division of Gastroenterology and Hepatology, Mayo Clinic Arizona, Phoenix, Arizona, USA.
  • Kleiner DE; Pacific Rim Pathology, San Diego, California, USA.
  • Ma C; Department of Pediatrics, University of California San Diego, La Jolla, California, USA.
  • McFarlane SC; Division of Gastroenterology and Hepatology, Mayo Clinic Arizona, Phoenix, Arizona, USA.
  • Noureddin M; Faculty of Medicine and Biomedical Sciences, University of Queensland, Brisbane, Queensland, Australia.
  • Ratziu V; Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Valasek MA; Harvard Medical School, Boston, Massachusetts, USA.
  • Younossi ZM; Division of Gastroenterology, Department of Medicine, University of Western Ontario, London, Ontario, Canada.
  • Harrison SA; Alimentiv Inc., London, Ontario, Canada.
  • Loomba R; Department of Epidemiology and Biostatistics, University of Western Ontario, London, Ontario, Canada.
Hepatology ; 76(4): 1150-1163, 2022 10.
Article em En | MEDLINE | ID: mdl-35332569
ABSTRACT
BACKGROUND AND

AIMS:

The NASH Clinical Research Network histologic scoring system, the gold-standard NASH histology assessment for clinical trials, has demonstrated intrarater and interrater variability. An expert panel in a previous systematic Research and Development/University of California Los Angeles (RAND/UCLA) study determined that existing histologic scoring systems do not fully capture NASH disease activity and fibrosis, and standardized definitions of histologic features are needed. We evaluated the reliability of existing and alternate histologic measures and their correlations with a disease activity visual analog scale to propose optimal components for an expanded NAFLD activity score (NAS). APPROACH AND

RESULTS:

Four liver pathologists who were involved in the prior RAND/UCLA study underwent standardized training and multiple discussions with the goal of improving agreement. They were blinded to clinical information and scored histologic measures twice, ≥2 weeks apart, for 40 liver biopsies representing the full spectrum of NAFLD. Index intraclass correlation coefficient (ICC) estimates demonstrated intrarater (0.80-0.85) and interrater (0.60-0.72) reliability. Hepatocyte ballooning items had similar interrater ICCs (0.68-0.79), including those extending scores from 0-2 to 0-4. Steatosis measures (interrater ICCs, 0.72-0.80) correlated poorly with disease activity. Correlations with disease activity were largest for hepatocyte ballooning and Mallory-Denk bodies (MDBs), with both used to develop the expanded NAS (intrarater ICC, 0.90; interrater ICC, 0.80). Fibrosis measures had ICCs of 0.70-0.87.

CONCLUSIONS:

After extensive preparation among a group of experienced pathologists, we demonstrated improved reliability of multiple existing histologic NAFLD indices and fibrosis staging systems. Hepatocyte ballooning and MDBs most strongly correlated with disease activity and were used for the expanded NAS. Further validation including evaluation of responsiveness is required.
Assuntos

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Assunto principal: Hepatopatia Gordurosa não Alcoólica Limite: Humans Idioma: En Revista: Hepatology Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Assunto principal: Hepatopatia Gordurosa não Alcoólica Limite: Humans Idioma: En Revista: Hepatology Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos